• NFlection Looks to Erase NF1 Tumors With Drug That Only Goes Skin Deep

    25 days ago - By Xconomy

    The first drug for neurofibromatosis type 1 is available to patients following the FDA's approval of the AstraZeneca treatment earlier this year. Biotech startup NFlection Therapeutics is vying to be runner-up, but its founders say they can eventually win out with a drug that takes a different approach than the commercialized pill while also offering a safer and more effective way of addressing the tumors and skin bumps caused by the rare disease. NFlection is developing its drug as a topical gel. CEO Christopher Powala says that unlike oral drugs that travel throughout the body and spark...
    Read more ...